Scholarlink

Purpose <p>To evaluate whether HPV vaccination prevalence among eligible U.S. individuals has increased steadily since vaccine introduction and to characterize trends across demographic subgroups.</p> Methods <p>Using National Health and Nutrition Examination Survey data (2007–August 2023) among individuals aged 9–26&#xa0;years, we assessed trends in HPV vaccination prevalence (≥ 1 dose) with joinpoint regression to identify inflection points and estimate annual percent changes (APCs). Analyses were stratified by sex, age, and race/ethnicity.</p> Results <p>Vaccination prevalence increased from 14.1% (95% CI, 10.1–19.3) in 2007–2008 to 49.1% (95% CI, 44.5–53.7) in 2021–2023 (APC, 6.8%; <i>p</i> = 0.001). Females experienced an early sharp rise (APC, 24.0%; <i>p</i> &lt; 0.001) through 2011–2012, followed by slower growth thereafter (APC, 3.7%; <i>p</i> = 0.004). Male vaccination increased steadily (APC, 11.3%; <i>p</i> &lt; 0.001). By 2021–2023, prevalence was highest among 13–17-year-olds (58.2%) and lowest among 9–12-year-olds (26.2%). Black individuals had the lowest vaccination prevalence of any racial/ethnic group (29.3%) and experienced a reversal of prior gains after 2015–2016 (APC, −&#xa0;2.3%; <i>p</i> = 0.34).</p> Conclusions <p>HPV vaccination prevalence more than tripled between 2007 and 2023, but the pace of growth slowed among females and reversed among Black individuals, which may exacerbate existing disparities in HPV-related cancer burden.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Changing pace of human papillomavirus vaccination among U.S. adolescents and young adults: the National Health and Nutrition Examination Survey, 2007–August 2023

  • 期刊论文

  • 发表日期：

    2025年12月27日

查看全文
  • Allan J. Zhang,
  • Jacqueline T. Nguyen,
  • Arthur S. Hong,
  • Kimberly Taing,
  • Danh Q. Nguyen

摘要

Purpose

To evaluate whether HPV vaccination prevalence among eligible U.S. individuals has increased steadily since vaccine introduction and to characterize trends across demographic subgroups.

Methods

Using National Health and Nutrition Examination Survey data (2007–August 2023) among individuals aged 9–26 years, we assessed trends in HPV vaccination prevalence (≥ 1 dose) with joinpoint regression to identify inflection points and estimate annual percent changes (APCs). Analyses were stratified by sex, age, and race/ethnicity.

Results

Vaccination prevalence increased from 14.1% (95% CI, 10.1–19.3) in 2007–2008 to 49.1% (95% CI, 44.5–53.7) in 2021–2023 (APC, 6.8%; p = 0.001). Females experienced an early sharp rise (APC, 24.0%; p < 0.001) through 2011–2012, followed by slower growth thereafter (APC, 3.7%; p = 0.004). Male vaccination increased steadily (APC, 11.3%; p < 0.001). By 2021–2023, prevalence was highest among 13–17-year-olds (58.2%) and lowest among 9–12-year-olds (26.2%). Black individuals had the lowest vaccination prevalence of any racial/ethnic group (29.3%) and experienced a reversal of prior gains after 2015–2016 (APC, − 2.3%; p = 0.34).

Conclusions

HPV vaccination prevalence more than tripled between 2007 and 2023, but the pace of growth slowed among females and reversed among Black individuals, which may exacerbate existing disparities in HPV-related cancer burden.